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Aim: A prospective, multicenter, post marketing surveillance study to evaluate the safety
and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS)
implanted during routine clinical practice in India.
Objectives: Primary objective:
1. To study the MACE and in stent and In-segment Loss at Six Months (in a pre selected
group of 50 patients).
Secondary objective:
1. Clinical and procedural success.
Materials and methods: This is a prospective, open label, single-arm,multicenter (16 sites), post
marketing observational study enrolling patients implanted with Superia-Sirolimus Eluting
Coronary Stent (SSECS) in routine clinical practice in India. A total of 200 Patients of coronary
Artery Disease (CAD) implanted with Superia-Sirolimus Eluting Coronary Stent (SSECS) were
enrolled. Clinical assessments were done at 30 days, 180 days and at 1, 2 years either tele-
phonically or office visit. A cohort of 50 pre-selectedpatientswere followed up for angiographic
evaluation at 180 days.
Results:MACE at 12 month of follow up was 1.71%.Late lumen loss, in segment was 0.14 and
in stent was 0.10 mm at 6 month of follow-up. TLR was required only in 2 patients.
Conclusion: Superia stent is as safe as other biodegradable polymer stent in the market and
time has come for biodegradable polymer stent with thin struts.
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i n d i a n h e a r t j o u rn a l 6 6 ( 2 0 1 4 ) 6 8 2e6 8 5 6831. IntroductionDrug-eluting stents continue to represent a major medical
advance for angioplasty (Serruyes et al, 2006).1 The findings of
large randomized clinical trials showing the re-stenosis
reduction efficacy of these stents have led to their approval
and use in India.2e5 Although rate of restenosis was lesser in
DES as compared to BMS,6 Sirolimus DES versus Paclitaxel
DES,7e10 still there was a scope of improvement.
The first generation DES initially demonstrated a good
promise in terms of reducing restosis. But over a period of
time, the polymeric degradation byproducts failed to bring
about endothelisation. Failure to endothelisation gave rise to
problem of nonhealing and restenosis.11e13 Currently DES
technology are targeted to minimize vascular injury during
stenting using ultra low strut thickness stent.14
Biodegradable polymer DES offer controlled elution of
active drug from the stent backbone by means of a biocom-
patible polymer coating, which after completion of its useful
function, slowly degrades to inert organic monomers, thereby
dissipating the risk associated with the long-term presence of
durable polymer in the coronary vessel wall.
Biodegradable polymer coatings are gaining popularity and
are in use to eliminate inflammation, stent thrombosis and
MACEwhile preserving the efficacy of DES. Superia-Sirolimus-
Eluting Coronary Stent System (SSECSS) is a device/drug
combination product comprised of four components: Stent
platform: Flexia L605Cobalt Chromium stent withmost recent
coronary stent designs with thin 65 micron struts, delivery
system, active drug component-sirolimus and biodegradable
polymers. This study was undertaken to study clinical and
procedural outcomes in patients implanted with Superia-
Sirolimus Eluting Coronary Stent (SSECS) in routine clinical
practice in India.2. Methods and materials
This was prospective, open label, single-arm, multicenter (16
sites), post marketing observational study enrolling patients
implanted with Superia-Sirolimus Eluting Coronary Stent
(SSECS) in routine clinical practice in India.2.1. General inclusion criteria were
1. Patient with age >18 years.
2. The patient who agrees to participate in the study.
3. Patients whose coronary anatomy were suitable for im-
plantation of one or more Superia-Sirolimus Eluting Coro-
nary Stent.2.2. Angiographic inclusion criteria
1. Target lesion must be located in native coronary artery
(2.5e3.5 mm)
2. Treatment of two de novo lesions, each located in a sepa-
rate native epicardial vessel.3. Target lesion(s) must measure < 28 mm by length by visual
estimation
4. The target lesion must be a major artery or branch with a
visually estimated stenosis of >70% and <100% with a timi
flow of >12.3. General exclusion criteria were-
1. Patient currently experiencing clinical symptoms consis-
tent with AMI or with acute myocardial infarction (AMI)
preceding the index procedure (CK-MB >2 times of upper
limit of normal) and CK and CK-MB not have returned to
the upper limit of normal at the time of procedure.
2. Patient with left ventricular ejection fraction (LVEF) of
<30%
3. Patient with heart transplant or any other organ trans-
plant or in waiting list of any organ transplant
4. Female patients with known pregnancy or who are
lactating.
5. Patients with known hypersensitivity or allergies to
aspirin, heparin, clopidogrel, ticlopidine, Sirolimus or
similar drugs, or any other analog or derivative, cobalt,
chromium, nickel, molybdenum or contrast media
6. Patients who are judged to have a lesion that prevents
complete inflation of an angioplasty balloon
7. Current medical condition with a life expectancy of less
than 12 months
8. Patients who are receiving immunosuppressive therapy
or have known serious immunosuppressive disease (eg
HIV) or have severe autoimmune disease that requires
chronic immunosuppressive therapy (eg SLE etc)
9. Patients who are receiving or plan to receive the chronic
anticoagulation therapy (eg heparin or coumadin)
10. Subject has received brachytherapy in any epicardial
vessel (including side branches)
11. Drug eluting stent treatment if done within 90 days
prior to the index procedure
12. Subject has known renal insufficiency (eg. Serum
creatinine level of >2.5 mg/dL or subject is under
dialysis)
13. Platelet count <1,00,000 cells/mm3 or >7,00,000 cells/
mm3, WBC of <3000 cells/mm3
2.4. Angiographic exclusion criteria
1. Patients with Chronic Total Occlusions (TIMI flow 0).
2. Patient with ostial left coronary artery and left main ostial
lesion (RCA-aorto ostial lesion are not excluded)
3. Patients with extreme angulation (90).
4. Patients with heavy calcification of target vessel
5. Patients with instent re-stenosis.
6. Patient with target vessel containing thrombus
7. Patient with arterial or saphenous vein graft lesion.
8. Patient with target lesion involving a bifurcation in which
side branch is  2 mm in diameter and the ostium of the
side branch is 50% stenosed by visual estimation
Treatment and procedures were done as per discretion of
the investigator. Safety data (death, MI, revascularization,
Table 2 e Mortality, morbidity and MACE.
1 Month FU
(n ¼ 200) (%)
6 Month FU
(n ¼ 200) (%)
1 Year
(n ¼ 175) (%)
Non cardiac death 0 1 (0.50%) 1 (0.57%)
Cardiac death 1 (0.50%) 1 (0.50%) 1 (0.57%)
Myocardial infarction 0 0 0
TVR 0 0 0
TLR 1 (0.50%) 2 (1%) 2 (1.14%)
Non e TVR 0 0 0
CABG 0 1 (0.50%) 1 (0.57%)
Device malfunction 0 0 0
Procedural success (100%) (100%) (100%)
Stent thrombosis 0 0 0
MACE % 2 (1.00%) 3 (1.5%) 3 (1.71%)
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definitions and unexpected adverse device effects) were
reviewed by independent safety monitoring board (person-
nel's not associated in any terms with the study organization
and conduct). A total of 200 Patients of coronary Artery Dis-
ease (CAD) implanted with Superia-Sirolimus Eluting Coro-
nary Stent (SSECS) were enrolled. Clinical assessments was
done at 30 days, 180 days and at 1, 2 years either telephonically
or office visit.
The following data were collected at the each follow up
visit-
1. Clinical events that occur during the procedure including
death, MI, revascularization and stent thrombosis
2. Adverse events (AE) data including laboratory test results,
ECG and subsequent repeat coronary angiogram
3. Patient compliance to anti-platelet therapy and any inter-
ruption of therapy
4. Major bleeding complications.
5. Patient health status (symptoms physical function, and
quality of life) using the Seattle angina Questionnaire.3. Results
A total of 200 patients enrolled across 16 centers in India.
First patients was enrolled in May 2012 and last patient in
November 2013 and study completed in April 2014. De-
mographic profile of 200 patients is shown in Table 1. Mean
age of patients were 56 yr, 82% were male, 38.5% were dia-
betic, 46% were hypertensive and 27% were having previous
MI.
Procedural success was achieved in all patients. At 1
year of follow up TLR was required only in 2 patients and
there was only 1 cardiac death and MACE was seen in 3
(1.71%) patients (Table 2). Angiographic follow was done in
50 patients. As shown in Table 3 late lumen loss studied at 6
month of follow up. In stent lumen loss was 0.10 mm and in
segment lumen loss was 0.014 mm at 6 month of follow up.4. Discussion
First generation DES were better than BMS, sirolimus DES fare
better than Paclitaxel DES, thin struts designed stent better
than thicker profile stents. When the data from present studyTable 1 e Demographics profile (200 patients).
Mean age, years 56 years
Male patients 164 (82 %)
Female patients 36 (18%)
Smokers 56 (28%)
Diabetic patients 77 (38.5%)
Hyperlipidemia 18 (9%)
Hypertension 92 (46%)
Previous MI 54 (27%)
History of previous stroke 4 (2%)
History of TIA 3 (1.5%)compared with other studies, Superia-Sirolimus Eluting Cor-
onary Stent System seems better or equivalent to other in
term ofMACE and TLR. As shown in SPIRIT-11 study.15 Xience-
v stent was having MACE of 2.7%, TLR of 1.8% as compared to
MACE of 1.71% and TLR OF 1.14% WITH SUPERIA stent. Simi-
larly superia stent fared better than endeavor resolute16 in
term of MACE (8.5% vs 1.7%) but TVR was slightly more (0.8%
vs 1.14%).
When compared with stents with biodegradable polymer
like Biomatrix stent17 (unique abluminal biodegradable poly-
mer) MACEwas lower (5.1 vs 1.71%) and TVRwas almost equal
(0.8 vs 1.14%).Similarly when compared with BIOMIME stent,18
a sirolimusDESwith thin struts (65micron) and biodegradable
polymer poly l lactic acid and poly l glycolic acid, SUPERIA
stent showed better MACE and TLR as shown in Table 4.
The results of meta analysis published in BMJ,19 with data
derived from 126 randomized trials and more than a quarter
million patient years of follow up, showed that biodegradable
polymer drug eluting stents are not superior to newer gener-
ation durable polymer drug eluting stents for either efficacy or
safety outcomes. Further randomized trials are required to
show the superiority of biodegradable polymer stents over
newer generation durable polymerDES and one biodegradable
polymer stent over other.
Thus we can conclude safely that Superia stent is as safe as
other stent system in the market or even slightly better in
term of MACE and finally time has come for thin struts design
stents with biodegradable stent.Table 3 e Angiographic follow up (50 patients).
In stent In segment
MLD Pre procedure 0.99 0.99
Post procedure 2.5 2.5
180 days follow up 2.39 2.36
% Stenosis Pre procedure 57.59% 57.59%
Post procedure 12.04% 11.71%
180 days follow up 15.14% 15.50%
% Area stenosis Pre procedure 80.66% 80.66%
Post procedure 22.42% 22.42%
180 days follow up 26.67% 27.88%
Late lumen loss (at 180 days follow up visit) 0.10 mm 0.14 mm
% Area loss (at 180 days follow up visit) 0% 5.45%
Table 4 e Comparison between Superia PMS and other DES.
Stent name MACE Late loss Cardiac death TLR
Superia PMS (6 month) (n ¼ 200) 1.50% 0.10 mm (at 6 month) 0.50% 1.00%
Superia PMS (1 year) (n ¼ 175) 1.71% 0.10 mm (at 6 month) 0.57% 1.14%
Xience V, spirit II (n ¼ 223) (1 year)15 2.7% 0.19 mm (at 6 months) 0% 1.8%
Xience V, spirit II (n ¼ 223) (2 year)15 6.4% 0.19 mm (at 6 months) 0.5% 3.7%
Endeavour resolute (n ¼ 130) (1 year)16 8.5% 0.22 mm (at 9 months) 0.80% 0.8%
Biomatrix (80 biomatrix subjects) (6 month)17 3.8% 0.19 mm (at 6 months) 0% 1.3%
Biomatrix (80 biomatrix subjects) (1 year)17 5.1% 0.19 mm (at 6 months) NA 0.8%
Biomime (n ¼ 242) (1 year)18 5.7% 0.15 mm (at 8 months) 0.50% 4.7%
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